Posted on

Octrado introduces its proprietary trading offering: “Your Skill. Our Capital”

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model
VICTORIA, Seychelles, Sept. 09, 2026 (GLOBE NEWSWIRE) — Octrado introduces its proprietary trading, a service that gives traders access to firm capital through a structured evaluation process. Under the model “Your Skill. Our Capital”, the platform positions itself between the retail trader and the funded-account system, with the emphasis placed on the operational layer – data environment, rule clarity, evaluation and payouts – rather than on headline account sizes alone.

By sf-admin
Posted on

Provectio accélère le développement de son centre de formation avec un catalogue enrichi

L’ESN Provectio franchit une nouvelle étape dans le développement de son centre de formation. Après l’obtention de la certification Qualiopi en début d’année, l’entreprise accélère son développement en enrichissant son catalogue de formations.  Après avoir initié son activité de centre de formation avec des sessions dédiées à Microsoft 365, Provectio étend désormais son offre à l’intelligence artificielle ainsi qu’à l’administration des systèmes d’information, afin d’accompagner les entreprises dans l’évolution de leurs compétences numériques.

By sf-admin
Posted on

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

SHENZHEN, CHINA, Sept. 09, 2026 (GLOBE NEWSWIRE) — On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.

By sf-admin